Statin Combined with Amlodipine Treats Primary Aldosteronism
A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment
About This Trial
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Amlodipine besylate
Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
Amlodipine besylate combined Spironolactone
6-month treatment of Amlodipine besylate combined with Spironolactone